A Dose-ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multicenter, Randomized, Double-Blind Study with a 1-year Open-label, Follow-up Period.

Recruitment & Eligibility

Status: ot Recruiting

Sex: Not specified

Target Recruitment: 93

Inclusion Criteria

For study inclusion, subjects must fulfill all eligibility criteria

1)Signed informed consent by a parent or a legal guardian

2)Age 1 to less than 6 years

3)Weight ³ 10 kg and £ 40 kg

4)SiSBP and/or SiDBP ³ 95th percentile and £ 20 mm Hg (systolic) and/or 10 mm Hg (diastolic) above the 95th percentile at screening and at randomization based on height-adjusted charts for age and gender (Appendices C through H)

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

The following exclude subjects from study participation:

1) Any situation, clinical condition or laboratory abnormality that, in the opinion of the investigator or sponsor, may interfere with the subject’s participation in the study or would pose a significant risk to the subject or interfere with the assessment of safety and efficacy endpoints

2) Weight < 10 kg and > 40 kg

3) Less than 80% compliance with study medication during single-blind placebo screening as assessed by residual medication volume

4) Hypertension secondary to pheochromocytoma, hyperthyroidism, or Cushing’s syndrome

5) Uncorrected coarctation of the aorta, bilateral renal artery stenosis, or unilateral renal artery stenosis in a single kidney

6) Estimated glomerular filtration rate (GFR) < 50 mL/min/1.73m2 based on the Schwartz Formula (Schwartz et al, 1987)

7) Renal transplant < 6 months prior to study entry

Subjects who have received a renal transplant ³ 6 months prior to study entry may participate in the study if: 1) renal function is stable, 2) estimated GFR >50 mL/min/1.73m2, 3) stable doses of immunosuppressive medications are anticipated throughout the 4-week, double-blind period of the study, 4) no episodes of acute allograft rejection have occurred within 30 days of study entry, and 5) the renal allograft has no documented renal artery stenosis

8) Nephrotic syndrome not in remission

9) Unstable insulin dependent diabetes mellitus

10) Known bleeding, coagulation, or platelet disorder that could interfere with blood sampling

11) Clinically significant valvular heart disease

12) Clinical diagnosis of heart failure

13) Clinically significant arrhythmia (eg, any arrhythmia requiring medical therapy or that causes symptoms)

14) Second or third degree AV block

15) Impaired liver function defined as either acute liver disease or chronic liver disease with persistent liver enzyme values greater than 1½ times the upper limit of the reference range for aspartate aminotransferase (AST) or alanine aminotransferase (ALT)

16) Known hypersensitivity to ARBs

17) Currently receiving an angiotensin receptor blocker or an angiotensin converting enzyme inhibitor that in the investigator’s judgement cannot safely be withdrawn during the study

Subjects receiving an angiotensin receptor blocker or an angiotensin converting enzyme inhibitor may be eligible if they undergo withdrawal of the antihypertensive medication over a 2-week washout period and subsequently meet BP inclusion/exclusion criteria.

Subjects currently receiving other classes of antihypertensive medications (eg, diuretics, calcium channel blockers or beta-blockers) and whose BP values meet inclusion/exclusion criteria may participate in the study while continuing their current antihypertensive medication regimen. Up to 2 concomitant antihypertensive medications are permitted. Doses and dose regimens of concomitant antihypertensive medications must remain unchanged during the 4-week double-blind period of the study.

18) Currently using, or used within 14 days prior to receiving double-blind medication, any concomitant medications which in the opi

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials